



Inter-Association Initiative (IAI)

ECO-PHARMACO-**STEWARDSHIP** (EPS)

How do pharmaceuticals enter the environment?



Objective: Providing knowledge and data enabling assessments of sustainability of pharmaceuticals



Pharmaceuticals can enter the environment at all stages of the product's life-cycle. Therefore, we believe that only a collaborative approach will allow us to meaningfully increase our mutual knowledge and understanding on how to minimise any potential impact, issue or concern that pharmaceuticals in the environment might pose.



PILLAR 1

ENCOURAGING FURTHER RESEARCH TO ASSESS THE IMPACT OF PIE

Intelligence-led Assessment of Pharmaceuticals in the Environment



- Public-private partnership with the European Commission under the umbrella of the Innovative Medicines Initiative (IMI).
- The project is being run from 2015-2018 and aims to develop a framework in which tools, assays and models could enable industry, regulators and interested academic researchers to identify and prioritise medicines that are most likely to present a risk for the environment.
- This multi-stakeholder project has created a database on environmental information including more than 2000 studies for hundreds of existing active pharmaceutical ingredients.
- You can find all details and the progress report on the project website: www.i-pie.org









PILLAR 2

MANAGING EFFLUENTS FROM PHARMACEUTICAL SITES EFFECTIVELY

- We are continuously implementing initiatives which further reduce discharges from manufacturing plants through the exchange of good practices. We identify improvement needs by a risk-based approach and take measures where needed.
- Coupled with this, we have developed a 'maturity ladder' aimed at helping companies and their suppliers to gauge their performance and continuously improve.
- Additionally, many of our members are actively involved in the Pharmaceutical Supply Chain Initiative
 (PSCI) (www.pscinitiative.org), a group of pharmaceutical and healthcare companies who have joined forces
 to promote responsible supply chain management and better business conditions across the industry.
- Furthermore, we continue to monitor the issue of environmental impacts from the production of antibiotics. We have initiated several health-based commitments and are working, directly or via our member companies, through the AMR Industry Alliance to manage potential risks.









PILLAR 3

LIFE-CYCLE ASSESSMENT OF THE ENVIRONMENTAL RISK

Extended Environmental Risk Assessment (eERA)

- The current legislation requires that a pharmaceutical company assess the environmental risk only
 theoretically and only once, before the drugs are approved and launched, or when they are going to be used
 in new indications or combinations. We want to extend this framework.
- We believe that the ERA should be reviewed and, if necessary, updated throughout the product's lifecycle to reflect the latest information on the product's potential impact on the environment.
- However, we believe the focus should be on the level of the substance entering the environment (not the
 product, as it is now) and that resources should be prioritised only on those substances that actually
 pose a potential risk to the environment.







medsdisposal easier than you think

#medsdisposal is a campaign to raise awareness on how to appropriately dispose of unused or expired medicines in Europe. A dedicated website and other virtual media material have been developed, providing information on current disposal schemes in European countries in a 'one-stop shop'.



This is a joint initiative between several European healthcare, industry and student organisations.

Most European countries have special medication disposal schemes in place in order to prevent pharmaceuticals from ending up in the environment. By using the interactive map on the webpage www.medsdisposal.eu you can easily find information for your country.





Summary

- Eco-Pharmaco-Stewardship (EPS) is the industryproposed approach to provide a framework of environmental stewardship for pharmaceuticals covering the life-span of a pharmaceutical product
- EPS effectively responds to environmental concerns around PIE without hindering access to medicines for patients





